Anticancer Drug Development, Getting Out from BottleneckDa-Yong Lu1*, Ting-Ren Lu2, Hong Zhu3, Jian Ding4, Bin Xu4, Hong-Ying Wu2, Shu-Yun Wu4 and Nagendra Sastry Yarla5
- *Corresponding Author:
- Da-Yong Lu
School of Life Sciences
Shanghai University, Shanghai 200444, PR China
E-mail: [email protected]
Received date: January 05, 2017; Accepted date: January 19, 2017; Published date: January 23, 2017
Citation: Lu D, Lu T, Zhu H, Ding J, Xu B, et al. (2017) Anticancer Drug Development, Getting Out from Bottleneck. Med Chem (Los Angeles) 7:001-006. doi: 10.4172/2161-0444.1000423
Copyright: © 2017 Lu D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Drug development as a sensitive thermometer represents the scientific and technical power-engines for any countries. As a result, drug manufacture (highly competitive area) is pillar industry for small-range of developed countries and highest medical expenditures worldwide. Nonetheless, new anticancer drug discovery, development and manufacture were entering into bottleneck stage two decades ago. A declining successful rate of phase II and phase III anticancer drug evaluations is the grimmest situation for most leading anticancer drug developers worldwide. Profit is down every years. Owing to all these kinds of undesired factors, anticancer drug developments manufacturing and licensing have been highly risky over the past two decades. This article addresses key factors affecting anticancer drug developments and possible roadmaps for drug screening model and routine updating in all relevant countries are especially speculated.